Regulus Therapeutics Inc (RGLS.OQ) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : GlobalData
$300.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Regulus Therapeutics Inc receives orphan drug designation for RG-012


Monday, 21 Jul 2014 08:00am EDT 

Regulus Therapeutics Inc:U.S. FDA granted orphan drug designation to RG-012.RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21, as a therapeutic for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.In near term, Regulus expects to initiate natural history of disease study to gather further information about progression of Alport syndrome and to inform future clinical development plans of RG-012, key program under Regulus' 'Clinical Map Initiative. 

Company Quote

2.89
0.02 +0.70%
4:00pm EDT